Skip to content

RVMDW

Revolution Medicines, Inc.

NASDAQ · Healthcare · Biotechnology · US

$9.76
−5.20%
Ask drillr

Year over year

Reported trailing growth

Revenue
EBITDA
EBIT
-81.3%
EPS
-96.5%
Free cash flow
Operating cash flow

Forward estimates

Based on analyst estimates

Revenue
EBITDA
+2.7%
EPS
+10.1%

Three-year CAGR

Revenue
EBITDA
-85.1%
EBIT
-71.5%
Net income
-88.5%
EPS
-66.2%
Free cash flow
-60.9%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026